A Phase 1/2, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single and Multiple Ascending Doses of AOC 1044 Administered Intravenously to Healthy Adult Volunte…

Part A:

Key Inclusion Criteria:

• Aged 18 to 55 years, inclusive, at the time of informed consent
• Body mass index (BMI) of 18.5 to 32.0 kg/m2

Key Exclusion Criteria:

• Clinically significant abnormalities in laboratory results, ECGs, or vitals
• Current or recent use of prescription or nonprescription drugs
• Positive drug/alcohol test at Screening or Day -1
• Elevated blood pressure (BP) >130/80 mmHg at Screening
• Participation in a clinical study in which an investigational product was received within 1 month of screening or 5 half-lives of the investigational product
• Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply

Part B:

Key Inclusion Criteria:

• Aged 7 to 27 years, inclusive, at the time of informed consent
• Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years
• Confirmation of DMD gene mutation amenable to exon 44 skipping
• Weight ≥ 23 kg

• Ambulatory or non-ambulatory

  • Ambulatory participants: LVEF ≥50% and FVC≥50%
  • Non-ambulatory participants: LVEF ≥45% and FVC≥40%
• PUL 2.0 entry item A ≥3
• If on corticosteroids, stable dose for 30 days before screening and throughout the study

Key Exclusion Criteria:

• Biceps brachii muscles unsuitable for biopsy
• Serum hemoglobin < lower limit of normal
• Uncontrolled hypertension or diabetes
• Prior treatment with any cell or gene therapy
• Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent
• Recently treated with an investigational drug
• History of multiple drug allergies